Dermatomyositis: Causes, Symptoms, Diagnosis, and Treatment

What is Dermatomyositis?

Dermatomyositis is a rare but serious autoimmune inflammatory disease that simultaneously affects the skin and the skeletal muscles. It belongs to a broader group of conditions known as idiopathic inflammatory myopathies (IIMs), diseases in which the body’s immune system attacks its own muscle and skin tissue, causing progressive inflammation and damage.

The name itself reflects the two defining features of the condition:

• Dermato– refers to the characteristic red-to-violet skin lesions that appear in sun-exposed areas of the body, such as the face, neck, hands, and trunk.
• –myositis refers to the inflammatory involvement of multiple muscles (polymyositis), particularly those of the shoulders and limbs.

Dermatomyositis can occur at any age, with two distinct incidence peaks:

1. Juvenile dermatomyositis (JDM): Affecting children, typically between 5 and 15 years of age. This form tends to have specific features and a generally more favorable prognosis compared to the adult form.
2. Adult dermatomyositis: Affecting adults, most commonly between 40 and 60 years of age. In adults, the disease may be associated with malignant tumors of internal organs, significantly worsening the prognosis.

Worldwide, dermatomyositis is estimated to affect approximately 1 in 100,000 people per year, with women being affected more frequently than men at a ratio of approximately 2:1. While it is a chronic condition requiring long-term management, early diagnosis and treatment significantly improve outcomes.

Understanding dermatomyositis, including its warning signs, diagnostic criteria, and treatment options, is essential for patients and their families. This guide provides a comprehensive, medically accurate overview designed to empower patients with reliable information.

---

Causes

Dermatomyositis is classified as an autoimmune disease, a condition in which the immune system, instead of protecting the body against external threats such as bacteria and viruses, mistakenly attacks the body’s own cells and tissues. In dermatomyositis, the immune system directs this abnormal attack primarily against the cells of the skin and the skeletal muscles, generating chronic inflammatory reactions in both tissues.

What Triggers the Autoimmune Attack?

The precise cause that triggers the autoimmune aggression in dermatomyositis is not fully understood. However, several factors and hypotheses have been proposed by researchers:

1. Viral Infections

Certain viral agents have been implicated as potential triggers. In particular, Coxsackie B viruses, which are the same viruses responsible for hand, foot, and mouth disease, have been associated with the onset of dermatomyositis in some patients. The hypothesis is that, in genetically predisposed individuals, the immune response mounted against the virus may lead to cross-reactivity with the body’s own muscle and skin antigens, a phenomenon known as molecular mimicry.

Other viral agents under investigation include:

• Picornaviruses
• Retroviruses
• Influenza viruses

2. Drug-Induced Dermatomyositis

Certain medications have been reported to trigger or precipitate dermatomyositis in susceptible individuals. The most well-documented example is D-penicillamine, a drug used in the management of severe rheumatoid arthritis and Wilson’s disease. Other drugs occasionally implicated include hydroxyurea, statins (in rare cases), and checkpoint inhibitor immunotherapies used in cancer treatment.

3. Paraneoplastic Mechanism

In adult patients, dermatomyositis is frequently associated with underlying malignancies. In these cases, the toxic substances produced by the tumor or the immune response directed against tumor antigens may trigger immune dysregulation that extends to attack muscle and skin tissue. This is referred to as paraneoplastic dermatomyositis, and it underscores the importance of cancer screening in all newly diagnosed adult patients.

4. Genetic Predisposition

Genetic factors appear to play a role in determining individual susceptibility to dermatomyositis. Specific HLA (human leukocyte antigen) alleles, genes that regulate immune responses, have been associated with increased risk. In particular, HLA-DR3 and HLA-B8 haplotypes have been more commonly found in patients with dermatomyositis compared to the general population.

5. Environmental Factors

Exposure to ultraviolet (UV) radiation is thought to contribute to disease flares, particularly the skin manifestations, in already-affected individuals. Physical stress, trauma, and other environmental exposures may also act as disease triggers or exacerbators in predisposed patients.

Is Dermatomyositis Contagious?

No. Dermatomyositis is not contagious. It cannot be transmitted from person to person through any form of contact, shared air, or bodily fluids. The inflammatory process is entirely driven by the patient’s own abnormal immune response, not by an infectious agent that can be spread.

Autoantibodies in Dermatomyositis

A particularly important diagnostic and prognostic development in recent years has been the identification of specific myositis-specific autoantibodies (MSAs) in the blood of dermatomyositis patients. These are antibodies produced by the patient’s immune system that target specific intracellular proteins. Different autoantibodies are associated with different clinical subtypes and prognoses:

The identification of these autoantibodies through blood tests has become an important tool in the diagnostic workup and clinical stratification of dermatomyositis patients.

---

Symptoms

The clinical presentation of dermatomyositis is characterized by skin and muscle involvement occurring simultaneously or in close temporal proximity. Skin manifestations may precede the muscle symptoms by weeks to months, or they may appear concurrently. In rare cases, skin involvement occurs without any muscle disease. This variant is known as amyopathic dermatomyositis (or dermatomyositis sine myositis).

The systemic nature of the disease means that internal organs may also be affected in more severe cases, as described in the dedicated section below.

Skin Manifestations and Symptoms

The cutaneous (skin) manifestations of dermatomyositis are highly characteristic and often allow experienced clinicians to suspect the diagnosis at first glance. The most distinctive features are:

1. Heliotrope Erythema

The term heliotrope (derived from the Greek word for “turning toward the sun”) describes the characteristic red-to-violet (lilac) rash that appears predominantly on sun-exposed skin areas. It is most commonly observed on:

• Eyelids (particularly the upper eyelids), where the rash may have a distinctive violet hue, sometimes described as the “heliotrope sign”
• Dorsum (back) of the hands, particularly over the knuckles (metacarpophalangeal and interphalangeal joints)
• Periungueal regions (skin surrounding the fingernails)

The rash may also extend to cover the entire face, the V-area of the neck and chest (the so-called “V-sign”), the upper back and shoulders (the “shawl sign”), knees, elbows, and the scalp (with or without associated alopecia).

The heliotrope erythema is often accompanied by:

• Fine scaling (desquamation)
• Edema (swelling) of the affected areas, particularly the periorbital (around the eyes) region. In some patients, eyelid swelling can be so pronounced that it partially closes the eye (narrows the palpebral fissure)
• A sensation of tension and/or itching (pruritus)

2. Gottron’s Papules

Gottron’s papules are one of the pathognomonic (uniquely characteristic) signs of dermatomyositis. They consist of:

• Erythematous (reddened), raised, confluent papules located on the dorsal surface of the hands, specifically overlying the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints, and occasionally the distal interphalangeal (DIP) joints
• The papules may also appear over the elbows, knees, and malleoli (ankles)
• They can have a violaceous (violet-red) or pink color and may develop central atrophy over time

Gottron’s sign refers to a similar but flat erythematous discoloration over the same joint surfaces, without the raised papular component.

3. Poikiloderma

In chronic forms of dermatomyositis, the active erythema gradually transitions into poikiloderma, a characteristic skin change involving:

• Skin atrophy (thinning of the skin)
• Telangiectasias (dilated superficial blood vessels, appearing as fine red lines or branching patterns visible through the skin)
• Hypopigmented areas (patches of skin that are lighter than normal, i.e., leukodermic areas)
• Fine scaling

Poikiloderma gives the affected skin a mottled, aged appearance and is most commonly seen in sun-exposed areas such as the chest and back.

4. Mechanic’s Hands

A distinctive but less frequently discussed manifestation is the so-called “mechanic’s hands”: rough, cracked, scaling, and darkened skin on the lateral and palmar surfaces of the fingers and hands, resembling the hands of a manual laborer. This feature is particularly associated with the antisynthetase syndrome (anti-Jo-1 antibody-positive disease).

5. Less Specific Cutaneous Manifestations

Other, less specific skin findings that may be observed in dermatomyositis include:

• Follicular keratotic papules (spinulosic dermatomyositis): Small, raised skin lesions with a rough surface, located on the face, trunk, and arms.
• Bullous (blistering) lesions: Rare, occurring only in the context of marked edema.
• Cutaneous calcinosis: Deposits of calcium salts in the subcutaneous tissue, forming hard plaques or nodules near joints. These can ulcerate, with white chalky material extruding through the skin. This complication is more common in juvenile dermatomyositis.
• Scleroderma-like patches: Areas of atrophic skin with deep induration (hardening), resembling systemic sclerosis (scleroderma).
• Mucosal lesions: Erythematous macules or erosions affecting the oral cavity (enanthem), erythema of the genitals and/or conjunctivae.
• Periungueal changes: Dilated capillary loops at the nail fold (visible with dermoscopy or even the naked eye), nail fold erythema, and ragged cuticles.
• Scalp involvement: Erythema, scaling, and pruritus of the scalp, sometimes with diffuse hair loss.

Muscle Manifestations and Symptoms

The muscular component of dermatomyositis is characterized by inflammation of the skeletal muscles (myositis), which leads to progressive weakness and, in the acute phase, pain.

Muscle Weakness (Myopathy)

The hallmark of dermatomyositis-related muscle involvement is proximal muscle weakness, which is weakness affecting the muscles closest to the center of the body (the proximal muscle groups), specifically:

• Shoulder girdle muscles: Making it difficult to raise the arms above the head, lift objects, or comb the hair
• Pelvic girdle and thigh muscles: Making it difficult to climb stairs, rise from a low chair or toilet seat, or get up from the floor

The weakness is typically symmetrical (affecting both sides of the body equally) and progressive over weeks to months.

In more severe cases, the following muscle groups may also be involved:

• Pharyngeal and esophageal muscles: Leading to dysphagia (difficulty swallowing) and an increased risk of aspiration pneumonia
• Respiratory muscles: Causing shortness of breath and, in severe cases, respiratory failure
• Facial muscles: Less commonly affected but possible in severe cases
• Neck flexor muscles: Causing difficulty holding the head upright (“dropped head syndrome”)

Muscle Pain (Myalgia)

In the acute phase, patients frequently experience muscle pain (myalgia), which is sometimes confused with joint inflammation (arthralgia/arthritis). The pain may be spontaneous or provoked by movement and palpation of the affected muscles.

Fatigue and General Weakness

Profound fatigue (asthenia) is a common and often debilitating symptom. Patients frequently report:

• Difficulty performing basic daily activities
• Inability to engage in previously tolerated physical exercise
• A general sense of exhaustion that does not improve with rest

Amyopathic Dermatomyositis

In approximately 20% of cases, patients present with the typical skin manifestations of dermatomyositis without any clinically significant muscle involvement. This form is known as amyopathic dermatomyositis or dermatomyositis sine myositis. These patients may still have subclinical muscle inflammation detectable through laboratory tests or imaging, but they do not develop functional muscle weakness. This variant is particularly associated with anti-MDA5 antibodies and carries a high risk of rapidly progressive interstitial lung disease.

Internal Organ Manifestations and Symptoms

While dermatomyositis primarily affects the skin and muscles, systemic involvement of internal organs can occur, particularly in severe or inadequately treated cases. These manifestations are less common but potentially serious:

Joints (Arthritis)

Inflammatory arthritis (joint pain, swelling, and stiffness) may occur in some patients with dermatomyositis. It typically affects the small joints of the hands and wrists and is usually non-erosive (does not cause permanent joint damage), unlike rheumatoid arthritis.

Heart (Cardiac Involvement)

Cardiac manifestations of dermatomyositis include:

• Tachycardia (rapid heart rate) and palpitations
• Arrhythmias and electrocardiographic (ECG) abnormalities
• Myocarditis (inflammation of the heart muscle) in severe cases
• Congestive heart failure (rare but possible in advanced disease)

Cardiac involvement may be clinically silent and detected only through routine monitoring.

Lungs (Pulmonary Involvement)

Pulmonary complications are among the most serious manifestations of dermatomyositis and include:

• Interstitial lung disease (ILD): A progressive scarring of the lung tissue that leads to breathlessness and reduced oxygen exchange. ILD is particularly associated with the anti-MDA5 and anti-Jo-1 antibody subtypes, and can be rapidly progressive and life-threatening.
• Aspiration pneumonia (pneumopathy ab ingestis): Caused by the aspiration of food or liquid into the airways due to weakness of the pharyngeal and esophageal muscles.
• Respiratory muscle weakness: In severe myositis, weakening of the intercostal and diaphragmatic muscles can impair breathing.

Gastrointestinal Tract

Involvement of the gastrointestinal system can manifest as:

• Dysphagia (difficulty swallowing, due to weakness of the pharyngeal and upper esophageal muscles)
• Altered bowel motility and transit (due to involvement of the smooth muscle of the gastrointestinal tract)
• Nausea, abdominal pain, and constipation in more severe cases

Raynaud’s Phenomenon

Some patients with dermatomyositis, particularly those with antisynthetase syndrome, also experience Raynaud’s phenomenon: episodic vasospasm of the fingers and toes in response to cold or stress. This causes color changes (white, then blue, then red) and discomfort.

---

Diagnosis

The diagnosis of dermatomyositis is based on a combination of clinical evaluation, laboratory tests, electrophysiological studies, and tissue biopsy. Specific diagnostic criteria must be met to confirm the diagnosis.

Diagnostic Criteria

The classical diagnostic criteria for dermatomyositis (modified Bohan and Peter criteria, 1975, still widely used) require the presence of:

1. Characteristic skin manifestations (heliotrope erythema, Gottron’s papules, Gottron’s sign)

2. Muscle weakness (hyposthenia/asthenia): Proximal, symmetrical, progressive

3. Elevation of muscle enzyme levels in serum:

   • Creatine phosphokinase (CPK/CK): The most sensitive and specific marker; may be elevated 5 to 50 times the upper limit of normal
   • Aldolase
   • Lactate dehydrogenase (LDH)
   • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (liver enzymes that are also elevated when muscle is damaged)

4. Characteristic electromyography (EMG) findings: Electromyography is a diagnostic test that evaluates the electrical activity of muscles. A sterile, disposable needle electrode is inserted into the muscle to record its electrical activity at rest and during contraction. In dermatomyositis/myositis, EMG typically reveals the characteristic triad:

   • Polyphasic potentials of reduced amplitude (indicating muscle fiber damage)
   • Fibrillation potentials at rest (indicating spontaneous, abnormal muscle activity)
   • Repetitive discharges (complex repetitive discharges)

5. Muscle biopsy histology: A skin biopsy alone is generally not diagnostic unless combined with a muscle biopsy. The muscle biopsy in dermatomyositis characteristically shows:

   • Perifascicular atrophy: Atrophy of muscle fibers at the periphery of muscle bundles, a hallmark feature of dermatomyositis
   • Inflammatory infiltrate: Predominantly composed of CD4+ T lymphocytes, B cells, and plasmacytoid dendritic cells, located around blood vessels (perivascular infiltrate) and in the connective tissue between muscle bundles
   • Capillary changes: Deposition of complement components (such as the membrane attack complex, MAC) on small blood vessels, which can be demonstrated by immunohistochemistry
   • Muscle fiber necrosis and regeneration

   Skin biopsy findings, while not independently diagnostic, can be highly suggestive when they show:

   • Vacuolization (vacuole formation) in epidermal cells
   • Dermal edema with perivascular inflammatory infiltrates
   • Epidermal atrophy

Levels of Diagnostic Certainty

Based on the number of criteria satisfied (in addition to the characteristic skin findings), the diagnosis is classified as:

Additional Diagnostic Tests

Beyond the classical criteria, the following investigations are important in the complete diagnostic workup:

Blood Tests

• Complete blood count (CBC): May show anemia and elevated white blood cell count in active disease
• Inflammatory markers: Elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)
• Myositis-specific autoantibodies (MSAs): Anti-Jo-1, anti-Mi-2, anti-MDA5, anti-TIF1-γ, anti-NXP-2, anti-SAE, and others are detected by specific immunological assays
• Myositis-associated autoantibodies (MAAs): Anti-Ro/SSA, anti-La/SSB, anti-U1-RNP, anti-PM/Scl
• Thyroid function tests: To exclude hypothyroid myopathy
• Kidney and liver function tests

Imaging Studies

• Magnetic Resonance Imaging (MRI) of muscles: MRI is increasingly used to detect and characterize muscle inflammation (edema and signal changes on STIR sequences). It is also useful for guiding the site of muscle biopsy to ensure sampling of affected tissue.
• Chest CT scan: Essential for detecting interstitial lung disease, which may be present even in the absence of respiratory symptoms
• Echocardiography: For the evaluation of cardiac involvement

Cancer Screening

Given the well-established association between adult dermatomyositis and internal malignancies, all newly diagnosed adult patients should undergo thorough cancer screening, which typically includes:

• CT scan of the chest, abdomen, and pelvis
• Mammography (in women)
• Gynecological examination with Pap smear and pelvic ultrasound (in women)
• Colonoscopy (depending on age and risk factors)
• Positron emission tomography (PET) scan in selected high-risk patients
• Serum tumor markers

Cancer screening should be repeated annually for at least 3 years after diagnosis, given that malignancy may develop after the initial dermatomyositis presentation.

---

Dermatomyositis and Pregnancy

The management of dermatomyositis in pregnant women presents unique clinical challenges, as the disease and its treatments can potentially affect both the mother and the developing fetus.

Published data on pregnancy outcomes in women with dermatomyositis are limited, reflecting the relative rarity of the disease. The most comprehensive study available to date is a large American cohort study that analyzed 853 women with dermatomyositis/polymyositis who were hospitalized for delivery, compared with an equal number of women from the general population.

Key Findings from the Study

The study (Kolstad et al., 2018) found the following:

• No significant differences between women with dermatomyositis/polymyositis and controls in rates of:
  • Premature rupture of membranes
  • Intrauterine growth restriction (IUGR)
  • Need for cesarean section
• However, women with dermatomyositis/polymyositis had a significantly higher risk of:
  • Hypertension during pregnancy (gestational hypertension and preeclampsia)
  • Longer hospitalization compared to women in the general population

Clinical Recommendations for Pregnant Patients

For women with dermatomyositis who are pregnant or planning pregnancy:

1. Pre-conception counseling: Women with dermatomyositis should discuss their plans for pregnancy with their rheumatologist and obstetrician before conceiving. Ideally, conception should occur during a period of sustained disease remission.

2. Disease activity monitoring: Close monitoring of disease activity throughout pregnancy is essential, as dermatomyositis can flare during pregnancy or the postpartum period.

3. Medication review: Some immunosuppressive drugs used in dermatomyositis are contraindicated during pregnancy (particularly methotrexate and mycophenolate mofetil, which are teratogenic). A safe medication regimen should be established before and during pregnancy.

4. Multidisciplinary care: Pregnant women with dermatomyositis should be managed by a multidisciplinary team including a rheumatologist, maternal-fetal medicine specialist (high-risk obstetrician), and, when needed, a pulmonologist and cardiologist.

5. Fetal monitoring: Enhanced fetal monitoring (additional ultrasound assessments, fetal growth scans) is recommended given the increased risk of complications.

6. Postpartum monitoring: The postpartum period carries a risk of disease flare; close follow-up with the rheumatologist is important after delivery.

---

Prognosis and Complications

Overall Prognosis

The prognosis of dermatomyositis is generally favorable when diagnosis is made early and treatment is initiated promptly. With adequate immunosuppressive therapy, most patients achieve significant improvement or even complete remission of their symptoms. However, dermatomyositis is a chronic relapsing-remitting condition, and many patients require long-term maintenance therapy.

Factors associated with a better prognosis include:

• Early diagnosis and treatment initiation
• Absence of internal organ involvement
• Absence of associated malignancy
• Presence of anti-Mi-2 antibodies (associated with good treatment response)
• Juvenile onset

Factors associated with a worse prognosis include:

• Associated malignancy (see below)
• Interstitial lung disease (especially rapidly progressive ILD associated with anti-MDA5 antibodies)
• Severe dysphagia and aspiration pneumonia
• Cardiac involvement
• Delayed diagnosis and treatment
• Presence of anti-MDA5 or anti-TIF1-γ antibodies

Association with Malignancy

One of the most clinically significant aspects of adult dermatomyositis is its well-established association with internal malignancies (cancers). Studies estimate that approximately 15–30% of adult patients with dermatomyositis have or will develop an underlying malignancy, typically within 3 years of the dermatomyositis diagnosis (either before or after).

The most commonly associated cancers differ by sex:

• In men: Lung cancer and gastric (stomach) cancer are the most frequent associations
• In women: Uterine cancer and ovarian cancer are the most commonly associated malignancies

Other associated cancers include breast cancer, colorectal cancer, non-Hodgkin’s lymphoma, and nasopharyngeal carcinoma (particularly in Asian populations).

In patients with cancer-associated dermatomyositis, the skin and muscle disease often responds to successful treatment of the underlying tumor, providing strong evidence that the malignancy is driving the autoimmune process.

Most Common Complications

The major complications of dermatomyositis include:

1. Infections: The most common complication, largely attributable to the immune-suppressing effects of the treatments used. Common infections include bacterial pneumonia, opportunistic infections (fungal, viral), and sepsis. Careful monitoring for infectious complications during treatment is essential.

2. Interstitial Lung Disease (ILD): Progressive pulmonary fibrosis can occur independently of aspiration, particularly in patients with anti-MDA5 or anti-Jo-1 antibodies. Rapidly progressive ILD is a life-threatening emergency.

3. Cardiac Complications: Including arrhythmias, myocarditis, and heart failure.

4. Aspiration Pneumonia: Secondary to pharyngeal muscle weakness and dysphagia.

5. Calcinosis: Particularly in juvenile dermatomyositis, calcium deposits in the skin and soft tissues near joints can cause pain, skin ulceration, and functional limitation.

6. Muscle Atrophy and Contractures: Chronic, inadequately treated myositis can lead to permanent muscle wasting (atrophy) and joint contractures, resulting in functional disability.

7. Medication Side Effects: Long-term corticosteroid therapy is associated with significant side effects, including osteoporosis, diabetes, hypertension, cataracts, weight gain, and adrenal suppression (see treatment section).

---

Treatment

The treatment of dermatomyositis requires a personalized, multidisciplinary approach tailored to the severity of the disease, the specific organs involved, the patient’s age, and the presence of associated conditions. The primary goals of treatment are:

• Control of active inflammation (skin and muscle disease)
• Prevention of disease-related complications (lung, heart, esophageal involvement)
• Minimization of treatment side effects
• Restoration of functional capacity and quality of life

First-Line Treatment: Corticosteroids

The cornerstone of dermatomyositis treatment remains systemic corticosteroid therapy (cortisone / prednisone). The standard initial (induction) dosage is:

• 0.5 to 1 mg/kg of body weight per day of prednisone (or equivalent), administered orally, typically in two divided daily doses

In severe cases with rapidly progressive muscle weakness, dysphagia, respiratory involvement, or acute interstitial lung disease, intravenous (IV) pulse methylprednisolone (1 gram per day for 3 consecutive days) may be administered as initial induction therapy before transitioning to oral prednisone.

Clinical improvement typically occurs within 1 to 6 weeks of initiating corticosteroid therapy. The key indicators of response include:

• Improvement in muscle strength
• Reduction in serum muscle enzyme levels (CPK, LDH, aldolase)
• Improvement in skin lesions

Tapering Corticosteroids

Gradual reduction (tapering) of the corticosteroid dose should begin only once muscle enzymes approach normal levels and clinical improvement has been sustained. The tapering process is typically slow (over many months) to avoid disease relapse.

The overall duration of corticosteroid therapy is usually 2 to 3 years. Both during treatment and upon tapering or discontinuation, disease flares (relapses) may occur, requiring a temporary increase in the corticosteroid dose.

Second-Line Treatment: Immunosuppressive Agents

In patients who:

• Fail to respond adequately to corticosteroids (steroid-resistant disease)
• Develop unacceptable steroid side effects
• Require a reduction in steroid dose (steroid-sparing strategy)
• Have severe or life-threatening disease features

Additional immunosuppressive agents are added, including:

Methotrexate (MTX)

• One of the most commonly used steroid-sparing agents in dermatomyositis
• Weekly low-dose oral or subcutaneous administration
• Effective for both skin and muscle manifestations
• Contraindicated in pregnancy (teratogenic)
• Requires monitoring of liver function and blood counts

Azathioprine (AZA)

• An oral immunosuppressant often used as an alternative or alongside MTX
• Particularly useful in patients with interstitial lung disease
• Generally well-tolerated; requires monitoring of blood counts and liver enzymes
• May be used with caution during pregnancy under specialist supervision

Cyclosporine

• A calcineurin inhibitor with both immunosuppressive and anti-inflammatory properties
• Particularly useful in cases with severe skin involvement or corticosteroid resistance
• Requires monitoring of blood pressure and kidney function

Cyclophosphamide

• Reserved for severe or rapidly progressive disease, particularly rapidly progressive interstitial lung disease
• Can be administered intravenously (pulse therapy) or orally
• Significant potential side effects including increased infection risk, bladder toxicity, and long-term risk of secondary malignancies

Mycophenolate Mofetil (MMF)

• Increasingly used as a steroid-sparing agent, particularly for skin manifestations and ILD
• Generally well-tolerated
• Contraindicated in pregnancy (teratogenic)

Anti-TNF Agents

• Tumor necrosis factor (TNF) inhibitors (such as infliximab, etanercept, adalimumab) have been used in refractory cases, particularly for the muscle manifestations
• Evidence is limited and results are variable

Intravenous Immunoglobulin (IVIG)

• High-dose intravenous immunoglobulin has been shown to be effective in dermatomyositis, both for skin and muscle manifestations
• Particularly useful in severe, refractory cases and when rapid improvement is needed
• Also used in patients with swallowing difficulties or respiratory compromise, where faster response is critical
• Generally well-tolerated; the main limitation is cost

Rituximab

• An anti-CD20 monoclonal antibody that depletes B lymphocytes
• Increasingly used in severe or refractory dermatomyositis, particularly in anti-synthetase syndrome and ILD
• Evidence from clinical trials (the RIM trial) showed benefit for muscle and skin manifestations in refractory patients

JAK Inhibitors

• Janus kinase (JAK) inhibitors (such as tofacitinib, baricitinib, and ruxolitinib) represent an emerging therapeutic option for dermatomyositis
• Particularly promising for refractory skin manifestations and anti-MDA5-associated ILD
• Clinical trials are ongoing

Treatment of Skin Manifestations

Skin manifestations in dermatomyositis may not always respond to systemic immunosuppressive therapy as well as the muscle component. Specific measures for managing skin disease include:

• Strict sun protection: UV radiation is a known trigger for skin manifestations. Daily use of broad-spectrum sunscreen (SPF 50+), protective clothing, and sun-protective behavior is strongly recommended for all patients.
• Topical corticosteroids: For localized skin lesions, topical steroids may provide symptomatic relief.
• Topical calcineurin inhibitors (tacrolimus, pimecrolimus): Useful for facial skin lesions where long-term topical steroid use is not advisable.
• Antimalarial drugs (hydroxychloroquine, chloroquine): Particularly effective for the skin manifestations of dermatomyositis and well-tolerated for long-term use. Require annual ophthalmological monitoring (rare risk of retinal toxicity).

Rehabilitation and Physical Therapy

Physical therapy and rehabilitation are integral components of dermatomyositis management:

• In the acute phase of active myositis, rest is recommended to avoid further muscle damage
• In the recovery phase, a graduated exercise program under the supervision of a physiotherapist helps restore muscle strength and functional capacity
• Resistance training and aerobic exercise have been shown to be safe and beneficial in patients with stable dermatomyositis
• Speech therapy may be required for patients with dysphagia
• Respiratory physiotherapy is important for patients with respiratory muscle involvement or ILD

Monitoring and Follow-Up

Long-term follow-up of dermatomyositis patients should include:

• Regular assessment of disease activity: Muscle strength testing, patient-reported outcomes, and skin evaluation at each visit
• Monitoring of muscle enzyme levels: CPK, LDH, aldolase at regular intervals
• Pulmonary function tests (PFTs) and HRCT of the chest: For monitoring ILD progression
• Cardiac evaluation: ECG and echocardiogram as clinically indicated
• Annual cancer screening for adult patients (for at least 3 years from diagnosis)
• Monitoring for medication side effects:
  • Bone density (DEXA scan) for patients on long-term corticosteroids
  • Blood glucose and blood pressure monitoring
  • Eye examination for hydroxychloroquine users (annual retinal screening)
  • Blood count and liver/kidney function for patients on immunosuppressants

---

Prevention

At present, there are no established preventive measures for dermatomyositis. Because the precise mechanisms triggering the autoimmune process are not fully understood, it is not possible to formulate specific recommendations that would prevent the development of the disease.

However, the following general measures can help patients with established dermatomyositis reduce the risk of flares and complications:

1. Rigorous sun protection: Limiting UV exposure is essential for all dermatomyositis patients, as sunlight can trigger and worsen skin manifestations. Broad-spectrum sunscreen (SPF 50+) should be applied daily, even on cloudy days, and protective clothing and hats should be worn.

2. Adherence to prescribed treatment: Following the treatment plan recommended by the rheumatologist/dermatologist is critical for maintaining disease remission and preventing relapse.

3. Infection prevention: Vaccinations (flu vaccine, pneumococcal vaccine, and others as recommended) are important in immunocompromised patients. Live vaccines should generally be avoided in patients on significant immunosuppressive therapy.

4. Osteoporosis prevention: Patients on long-term corticosteroids should take calcium and vitamin D supplements, follow weight-bearing exercise recommendations, and undergo regular bone density monitoring.

5. Regular medical follow-up: Consistent monitoring by a multidisciplinary team (rheumatologist, dermatologist, pulmonologist, and others as needed) is essential for early detection of complications and timely treatment adjustments.

6. Healthy lifestyle: Maintaining a balanced diet, healthy body weight, and adequate physical activity (within the limits allowed by disease activity) supports overall health and immune function.

7. Psychological support: Living with a chronic autoimmune disease can be emotionally challenging. Access to psychological support, patient support groups, and mental health resources is an important component of holistic care for dermatomyositis patients.

---

Frequently Asked Questions (FAQ)

Is dermatomyositis a fatal disease?

Dermatomyositis is a serious disease, but with modern treatments most patients achieve good disease control and a significantly improved quality of life. However, the prognosis can be more severe in patients with associated malignancy, rapidly progressive interstitial lung disease, or severe cardiac involvement. Early diagnosis and treatment are the most important factors for a favorable outcome.

Can dermatomyositis be cured?

There is currently no definitive cure for dermatomyositis in the strict sense. However, many patients achieve sustained remission, meaning the disease is well-controlled and symptoms are absent or minimal, with appropriate treatment. Some patients may eventually be able to discontinue treatment, while others require long-term maintenance therapy to prevent relapse.

Is dermatomyositis the same as polymyositis?

Dermatomyositis and polymyositis are closely related but distinct conditions. Both are forms of inflammatory myopathy, but dermatomyositis is characterized by the presence of specific skin manifestations (heliotrope erythema, Gottron’s papules), while polymyositis involves muscle inflammation without the characteristic skin changes. The underlying mechanisms and histological patterns also differ.

Can children get dermatomyositis?

Yes. Juvenile dermatomyositis (JDM) is a well-recognized form of the disease that affects children, typically between 5 and 15 years of age. JDM shares many features with the adult form, but it tends to have a more prominent calcinosis component. Unlike adult dermatomyositis, it is generally not associated with internal malignancy.

Can I exercise if I have dermatomyositis?

Exercise should be tailored to the phase of the disease. During active myositis, rest is recommended to prevent further muscle damage. During remission or recovery, a graduated, supervised exercise program that includes both resistance training and aerobic exercise is safe, beneficial, and recommended. Always discuss exercise plans with your rheumatologist and physiotherapist.

Will dermatomyositis affect my ability to work?

This depends on the severity of the disease, the muscles affected, and the nature of the work. Many patients with well-controlled dermatomyositis are able to maintain their employment. However, during flares or in severe cases with significant muscle weakness, temporary or long-term work limitations may be necessary. Occupational therapy can help patients adapt their work environment and activities.

---

Sources and Bibliography

• Cainelli T., Giannetti A., Rebora A. Manuale di dermatologia medica e chirurgica. McGraw-Hill, 4th edition.
• Saurat J., Grosshans E., Laugier P., Lachapelle J. Dermatologia e malattie sessualmente trasmesse. Italian edition edited by Girolomoni G. and Giannetti A. Third edition 2006. Masson.
• Wolff K., Johnson R., Saavedra A. Fitzpatrick Manuale ed Atlante di Dermatologia clinica. Italian edition of the seventh English-language edition, edited by Mauro Alaibac. Piccin 2015.
• Kolstad KD, Fiorentino D, Li S, Chakravarty EF, Chung L. Pregnancy outcomes in adult patients with dermatomyositis and polymyositis. Semin Arthritis Rheum. 2018;47(6):865-869. doi: 10.1016/j.semarthrit.2017.11.005.
• Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292(7):344–347. doi: 10.1056/NEJM197502132920706.
• Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955–1964.
• Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372(18):1734–1747.
• Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65(1):25–34.
• Rider LG, Miller FW. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA. 2011;305(2):183–190.
• Oldroyd AGS, Lilleker JB, Amin T, et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology (Oxford). 2022;61(5):1760–1768.